Understanding the chemical definition of NAD+ is only the beginning. The more practical question is: what does NAD+ actually do inside living cells? It helps transport electrons, supports enzymes involved in metabolism and cellular repair, and is constantly recycled and resynthesised as it is used by cells.
In this article, we explain step by step the mechanism of action of NAD+, including its role as a coenzyme, the relationship between NAD+ and NADH, its involvement in ATP production, its connection with sirtuins, NAD+ biosynthesis, and what can happen when NAD+ availability declines.
1. NAD+ as a Coenzyme – What Does That Actually Mean?
The terms enzyme, cofactor and coenzyme are sometimes used interchangeably, but they describe different things. Understanding these differences makes it much easier to explain the role of NAD+.
Enzymes are usually proteins, although some RNA molecules can also function as enzymes. Their role is to catalyse, or speed up, specific chemical reactions. NAD+ is not an enzyme because it does not catalyse such reactions on its own.
Cofactors are non-protein substances that some enzymes need to function properly. They can be metal ions, such as zinc or magnesium, as well as organic molecules.
Coenzymes are a special type of cofactor. They are organic, carbon-containing helper molecules, often derived from vitamins, that directly participate in enzymatic reactions. They can transfer electrons, chemical groups, or other components from one reaction to another. [1]
NAD+ belongs precisely to this third category.
It is a coenzyme, or more precisely, one of the most important electron-carrying coenzymes in the body. NAD+ cannot carry out metabolic reactions on its own, but hundreds of enzymes depend on it. The most important of these include enzymes known as dehydrogenases. [1,2]
If the NAD+-dependent dehydrogenase does not have a sufficient amount of available NAD+, its ability to carry out a given reaction may be limited. For this reason, cellular metabolism depends not only on the presence of appropriate enzymes, but also on maintaining an adequate availability of the coenzymes needed for their function.
2. How does NAD+ Transfer Electrons in Redox Reactions?
The best-known function of NAD+ is the transport of electrons during oxidation and reduction reactions, also referred to as redox reactions.
When nutrients such as glucose and fatty acids are broken down, dehydrogenase enzymes often need to take electrons from one molecule and transfer them elsewhere.
NAD+ enables such a transfer.
During the reaction, NAD+ accepts electrons and a hydrogen equivalent at a specific site on its nicotinamide ring. As a result of this reduction reaction, NAD+ is converted into NADH. [1,2]
This relationship can be simplified as follows:
NAD+ → accepts electrons → NADH
NADH can then transfer high-energy electrons to a subsequent reaction. In energy metabolism, one of the most important sites for their utilisation is the mitochondrial electron transport chain.
After donating electrons, NADH is reoxidised to NAD+. The recovered NAD+ can then take part in another metabolic reaction.
A continuous cycle is thus created:
NAD+ → NADH → NAD+
Instead of being used only once, the molecules repeatedly cycle between the oxidised and reduced forms.
Scientists have developed specialised experimental tools enabling the tracking and modification of these redox processes in specific cellular compartments, including the cytoplasm and mitochondria. These studies have shown that cellular problems can result not only from the absolute amount of NAD+, but also from an imbalance between NAD+ and NADH. [3]
An excessively reduced cellular environment can, for example, contribute to a condition known as reductive stress.
This is one of the reasons why NAD+ is sometimes described as a molecule at a metabolic crossroads. Its redox cycle links nutrient metabolism with mitochondrial energy production, while NAD+ itself also participates in distinct signalling and cell repair pathways.
3. What Role Does NAD+ Play in ATP Production and Cellular Energy?
The ability of NAD+ to transport electrons is closely linked to ATP production.
ATP, or adenosine triphosphate, is one of the main forms of useful chemical energy in cells.
NAD+ and NADH are involved in several interrelated stages of energy metabolism.
Glycolysis
Glycolysis takes place in the cytoplasm and involves breaking down glucose into smaller molecules.
During this process, NAD+ accepts electrons and is converted into NADH. Glycolysis also directly produces a relatively small amount of ATP.
Citric Acid Cycle
Products derived from glucose, fatty acids and certain amino acids can enter mitochondrial metabolism and be utilised in the citric acid cycle, also known as the Krebs cycle or TCA cycle.
Significant quantities of reduced electron carriers, primarily NADH, are produced in this cycle.
Oxidative Phosphorylation
Electrons transported by NADH can then enter the mitochondrial electron transport chain.
NADH passes electrons to complex I. As the electrons move along the respiratory chain, the released energy helps to pump protons across the inner mitochondrial membrane.
In this way, an electrochemical proton gradient is formed.
ATP synthase then uses the energy stored in this gradient to produce ATP. [1,2]
So NAD+ is not directly cellular energy. However, its ability to accept and transport electrons helps cells extract useful energy from nutrients and ultimately produce ATP.
Metabolic tracing studies have also demonstrated that the NAD+ turnover rate varies significantly between tissues. [4]
This has a biological rationale, as individual tissues have different energy requirements and metabolic characteristics. For this reason, a change in NAD+ availability does not necessarily produce identical effects in every organ.
Tissue with a high metabolic rate may react differently than tissue with a significantly lower energy demand.
4. What is the Link Between NAD+, Sirtuins, and Ageing Research?
NAD+ also plays an important function not directly related to electron transport. It is an essential substrate for enzymes known as sirtuins.
This relationship is one of the main reasons for the interest in NAD+ in ageing and longevity research.
Seven sirtuins are known in humans, designated as SIRT1–SIRT7. They are distributed in various cellular compartments, including the cell nucleus, cytoplasm, and mitochondria.
Sirtuins are involved in processes including:
- gene expression regulation;
- mitochondrial biology;
- cellular stress response;
- inflammatory signalling;
- DNA repair;
- metabolic regulation. [5]
Many reactions catalysed by sirtuins involve the removal of acetyl groups from proteins, a process known as deacetylation.
Unlike the role of NAD+ in redox reactions, in which NAD+ and NADH interchange between oxidised and reduced forms, sirtuin reactions consume NAD+ as a substrate.
One of the emerging products is nicotinamide.
This creates a direct biochemical link between intracellular NAD+ availability and the activity of NAD+-dependent sirtuins. If the amount of NAD+ is restricted sufficiently, these enzymes may not function at normal efficiency. [5,6]
Individual sirtuins have been studied in various biological contexts.
SIRT1 has generated significant interest due to its involvement in the regulation of metabolism and the cellular response to stress. SIRT2 has been studied in the context of protein acetylation and oxidative stress biology. SIRT3 is located primarily in the mitochondria and has been extensively analysed in research on mitochondrial metabolism, NAD+ and ageing-related processes. [5–7]
The research also covered interactions between sirtuin pathways and CD38, an enzyme capable of consuming NAD+.
Animal research also contributed to interest in this area. In one influential experiment, it was found that the NAD+ precursor, nicotinamide riboside, affected mitochondrial stress response pathways and improved certain parameters relating to stem cells and lifespan in experimental models. [8]
However, this mechanism should not be simplified to the statement that increasing NAD+ automatically increases sirtuin activity and, consequently, extends human life.
The biochemical link between NAD+ and sirtuins is well documented, but an increase in human lifespan through interventions that raise NAD+ levels has not been demonstrated.
5. How the Body Produces NAD+
The organism is not dependent on obtaining ready-made NAD+ directly from food. Instead, cells constantly produce and recycle it through several biosynthetic pathways.
Two particularly important mechanisms are the salvage pathway and de novo synthesis.
NAD+ Salvage Pathway
The salvage pathway is one of the main ways of maintaining NAD+ in many tissues.
When enzymes such as sirtuins and PARPs consume NAD+, one of the breakdown products can be nicotinamide.
Instead of simply getting rid of nicotinamide, cells reuse it.
The NAMPT enzyme, or nicotinamide phosphoribosyltransferase, converts nicotinamide into nicotinamide mononucleotide, commonly referred to as NMN.
NMN is then converted into NAD+ by NMNAT enzymes. [1,2]
This trail can therefore be simplified as follows:
Nicotinamide → NMN → NAD+
This recycling system helps cells constantly replenish NAD+ after it has been consumed.
Compounds related to vitamin B3 can also participate in the biosynthesis of NAD+ via interconnected pathways. These include niacin, nicotinamide, nicotinamide riboside (NR) and NMN.
They enter NAD+ metabolism at different biochemical stages and not all of them follow the exact same conversion pathway.
De Novo NAD+ Synthesis
The body can also produce NAD+, starting from the amino acid tryptophan.
This process takes place via the kynurenine pathway.
Tryptophan goes through several metabolic stages that ultimately lead to the production of quinolinic acid. The QPRT enzyme, or quinolinate phosphoribosyltransferase, then helps direct this pathway towards the production of NAD+. [9]
Under typical conditions in adults, this pathway usually plays a smaller role in the ongoing maintenance of NAD+ than recycling mechanisms.
However, this does not mean it is biologically insignificant.
Research into genetic defects of enzymes responsible for de novo NAD+ synthesis has linked severe disruptions of this pathway to congenital defects in animal models and rare human cases. These findings suggest that adequate de novo NAD+ synthesis may be of particular importance during embryonic development. [9,10]
The organism therefore maintains NAD+ through interconnected systems rather than a single source.
Cells can both salvage NAD+ breakdown products and synthesise new NAD+ from precursors derived from diet and metabolism.
6. What Happens When NAD+ Levels Drop?
Because NAD+ is involved in energy metabolism, DNA repair, redox balance and cell signalling, a decrease in its availability can potentially affect several biological systems simultaneously.
However, the consequences depend on the type of tissue, the degree of deficiency, the NAD+/NADH balance and the overall physiological state.
Energy metabolism
Reduced NAD+ availability may disrupt reactions requiring NAD+ as an electron acceptor.
This may ultimately affect mitochondrial metabolism and cellular energy production.
Experimental studies indicate, however, that some tissues have a significant capacity to buffer such changes. A measurable drop in NAD+ does not therefore necessarily cause an immediate or proportional deterioration in physiological function. [4]
Cardiovascular System Biology
Cardiovascular studies analyse not only the absolute concentrations of NADH or NAD+, but also the balance between them.
Changes in the NADH to NAD+ ratio have been linked to changes in the regulation of mitochondrial proteins in heart failure studies involving both experimental models and human heart tissue. [11]
These observations indicate a link with cardiovascular metabolism, but do not prove that NAD+ supplementation is a treatment for heart failure.
Neurological Examinations
NAD+ metabolism is also generating significant interest in neuroscience.
Reduced NAD+ availability has been experimentally linked to mitochondrial dysfunction and neuroinflammatory pathways relevant to diseases such as Parkinson's and Alzheimer's.
Early clinical trials analysed whether NAD+ precursors could influence NAD+ metabolism in the brain of people with Parkinson's disease. In some studies, measurable changes in NAD+-related metabolism in the brain were noted after administration of the precursors. [12,13]
These results remain experimental and should not be interpreted as proof that increasing NAD+ cures Parkinson's disease, Alzheimer's disease or other neurological disorders.
DNA repair
PARPs, or poly(ADP-ribose) polymerases, represent another important group of NAD+-consuming enzymes.
Some PARP enzymes activate in response to DNA damage and use NAD+ in signalling related to repair processes.
Because DNA damage accumulates over a lifetime, increased PARP activity can lead to greater consumption of NAD+.
This creates the possibility of competition between various NAD+-dependent systems. PARP, sirtuins, CD38 and other NAD+-consuming enzymes ultimately draw upon the cellular reserves of this molecule. [14]
Researchers therefore proposed that increased consumption of NAD+ may contribute to the age-related decline in its availability.
Much of this mechanistic evidence comes from cellular and animal studies. Human studies confirm changes in NAD+ metabolism associated with ageing and certain disease states, but their clinical significance and the possibility of reversing these changes remain the subject of ongoing research.
7. What Is the Relationship Between NAD+ and FAD?
NAD+ and FAD are important electron-carrying coenzymes, but they are derived from different vitamin precursors and participate in cellular metabolism in different ways.
FAD stands for flavin adenine dinucleotide.
NAD+ is closely linked to vitamin B3 metabolism, whereas FAD is derived from riboflavin, which is vitamin B2.
FAD also accepts electrons during metabolic reactions. Its reduced form is FADH2. [1,2]
Both NADH and FADH2 ultimately deliver electrons to mitochondrial energy production processes, but they enter the electron transport chain at different points.
NADH transfers electrons primarily to complex I.
FADH2 supplies electrons via complex II.
Because FADH2 enters the respiratory chain at a later stage, its electrons typically contribute to the pumping of fewer protons, and thus to the production of less ATP than the electrons delivered by NADH to complex I.
NAD+ and FAD are therefore parallel elements of cellular bioenergetics, rather than interchangeable molecules.
Their relationship is also useful in experimental research. Scientists can measure the natural fluorescence associated with reduced NAD(P)H and oxidised FAD to assess the metabolic state of cells and tissues. Such optical methods provide information on changes in redox metabolism without treating either of these coenzymes as a simple, standalone marker. [15]
Mechanism of Action of NAD+ at a Glance
| Trial | The role of NAD+ |
|---|---|
| Redox reactions | It accepts electrons and is converted into NADH |
| Glycolysis | It supports oxidation reactions during glucose metabolism. |
| Citric acid cycle | It helps to collect high-energy electrons in the form of NADH |
| Electron transport chain | NADH delivers electrons to complex I |
| ATP production | It indirectly supports the proton gradient utilised by ATP synthase |
| Sirtuins | It acts as an essential, consumed substrate |
| PARP | Delivers NAD+ for signalling related to DNA damage |
| Recovery trail | NAD+ is regenerated from recovered nicotinamide |
| de novo pathway | NAD+ can be synthesised via tryptophan metabolism |
| Cellular redox balance | The NAD+/NADH ratio helps to regulate the metabolic state |
| Association with FAD | Both are vitamin-derived electron carriers, but they participate in different pathways |
The most important thing is that NAD+ performs more than one biological function. During metabolism it acts as a repeatedly used electron carrier, whilst at the same time being consumed as a substrate by important enzymes responsible for signalling and repair processes.
Limitations of Current Evidence
A significant portion of detailed knowledge regarding sirtuin activity, the competition between PARP and other NAD+-consuming enzymes, and the balance between the salvage pathway and de novo NAD+ synthesis comes from studies on cell cultures and animal models. The extent to which individual mechanisms translate to various human tissues and disease states is still being investigated. [5,6,9]
The relationship between the decline in NAD+ and cardiovascular or neurological diseases is also complex. Mechanistic links do not mean that low NAD+ levels are the main cause of a disease, nor that therapeutically increasing NAD+ will reverse it. Larger, controlled human trials are needed to confirm such effects. [11–13]
Experimental results also show that even a significant reduction in NAD+ does not always lead to as large a deterioration in function as might be expected. This suggests that tissues may possess a metabolic reserve, and that the concentration of NAD+ alone does not fully determine their functioning. [4]
Finally, evidence indicating the importance of de novo NAD+ synthesis during embryonic development comes largely from genetic studies and animal models. Corresponding data in humans are limited primarily to rare congenital disorders involving the respective enzymes. [9,10]
Disclaimer
This article is for educational and scientific-information purposes only. It does not constitute medical advice, a diagnosis, treatment guidelines, dosage instructions, or a recommendation regarding the use of NAD+, NR, NMN, niacin, nicotinamide, or any other NAD+-related compounds.
Research into NAD+ encompasses both well-established biochemical mechanisms and the results of cellular, animal and human studies, which vary in level and quality of evidence. Changes in NAD+ metabolism, sirtuin activity, mitochondrial function or other cellular pathways should not be interpreted as proof that increasing NAD+ levels prevents, treats or reverses ageing, cardiovascular disease, neurological disorders, metabolic diseases or any other conditions.
Interventions aimed at increasing NAD+ levels and their long-term clinical effects remain the subject of active research. The results of mechanistic studies and an increase in measured NAD+ levels do not necessarily translate into significant health benefits in humans.
References
- Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
- Titov, D. V., et al. (2016). Complementation of mitochondrial electron transport chain dysfunction by manipulation of the NAD+/NADH ratio. Science, 352(6282), 231–235. https://pubmed.ncbi.nlm.nih.gov/27124460/
- Liu, L., et al. (2018). Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metabolism, 27(5), 1067–1080. https://pubmed.ncbi.nlm.nih.gov/29685734/
- Lemos, V., et al. (2017). The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes. Human Molecular Genetics, 26(21), 4105–4117. https://pubmed.ncbi.nlm.nih.gov/28973648/
- Liu, G., et al. (2016). Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy. Antioxidants & Redox Signaling, 26(15), 849–863. https://pubmed.ncbi.nlm.nih.gov/27460777/
- Camacho-Pereira, J., et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127–1139. https://pubmed.ncbi.nlm.nih.gov/27304511/
- Zhang, H., et al. (2016). NAD+ repletion improves mitochondrial and stem cell function and enhances lifespan in mice. Science, 352(6292), 1436–1443. https://pubmed.ncbi.nlm.nih.gov/27127236/
- Szot, J. O., et al. (2020). Bi-allelic mutations in NADSYN1 cause multiple organ defects and expand the genotypic spectrum of congenital NAD deficiency disorders. American Journal of Human Genetics, 106(1), 129–136. https://pubmed.ncbi.nlm.nih.gov/31883644/
- Cuny, H., et al. (2020). Gene-environment interactions and NAD+ deficiency cause congenital malformations and miscarriage in mice. Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/32015132/
- Lee, C. F., et al. (2016). Normalisation of NAD+ redox balance as a therapy for heart failure. Circulation, 134(12), 883–894. https://pubmed.ncbi.nlm.nih.gov/27489254/
- Brakedal, B., et al. (2022). The NADPARK study: a randomised phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism, 34(3), 396–407. https://pubmed.ncbi.nlm.nih.gov/35235774/
- Hou, Y., et al. (2021). NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS-STING. Proceedings of the National Academy of Sciences, 118(37). https://pubmed.ncbi.nlm.nih.gov/34497121/
- Koczor, C. A., et al. (2021). Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly are modulated by the PARP/NAD+/SIRT6 axis. Cell Reports, 37(5), 109917. https://pubmed.ncbi.nlm.nih.gov/34731617/
- Wallrabe, H., Svindrych, Z., Alam, S. R., et al. (2018). Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Scientific Reports, 8, 79. https://pubmed.ncbi.nlm.nih.gov/29311591/